PMID- 36921105
OWN - NLM
STAT- MEDLINE
DCOM- 20231006
LR  - 20231006
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 136
IP  - 19
DP  - 2023 Oct 5
TI  - Flare and change in disease activity among patients with stable rheumatoid 
      arthritis following coronavirus disease 2019 vaccination: A prospective Chinese 
      cohort study.
PG  - 2324-2329
LID - 10.1097/CM9.0000000000002562 [doi]
AB  - BACKGROUND: Vaccination has been shown effective in controlling the global 
      coronavirus disease 2019 (COVID-19) pandemic and reducing severe cases. This 
      study was to assess the flare and change in disease activity after COVID-19 
      vaccination in patients with stable rheumatoid arthritis (RA). METHODS: A 
      prospective cohort of RA patients in remission or with low disease activity was 
      divided into a vaccination group and a non-vaccination group based on their 
      COVID-19 vaccination status. Each of them was examined every 3 to 6 months. In 
      the vaccination group, disease activity was compared before and after 
      vaccination. The rates of flare defined as disease activity scores based on 
      28-joint count (DAS28) >3.2 with DeltaDAS28 >/=0.6 were compared between vaccination 
      and non-vaccination groups. RESULTS: A total of 202 eligible RA patients were 
      enrolled. Of these, 98 patients received no vaccine shot (non-vaccination group), 
      and 104 patients received two doses of vaccine (vaccination group). The median 
      time interval from pre-vaccination visit to the first immunization and from the 
      second dose of vaccine to post-vaccination visit was 67 days and 83 days, 
      respectively. The disease activity scores at pre-vaccination and post-vaccination 
      visits in the vaccination group patients were similar. At enrollment, gender, RA 
      disease course, seropositivity, and disease activity were comparable across the 
      two groups. Flare was observed in five (4.8%) of the vaccination group patients 
      and nine (9.2%) of the non-vaccination group patients at post-vaccination 
      assessment ( P  = 0.221). In terms of safety, 29 (27.9%) patients experienced 
      adverse events (AEs) after vaccination. No serious AEs occurred. CONCLUSIONS: 
      COVID-19 vaccinations had no significant effect on disease activity or risk of 
      flare in RA patients in remission or with low disease activity. Patients with 
      stable RA should be encouraged to receive the COVID-19 vaccination.
CI  - Copyright (c) 2023 The Chinese Medical Association, produced by Wolters Kluwer, 
      Inc. under the CC-BY-NC-ND license.
FAU - Geng, Yan
AU  - Geng Y
AD  - Department of Rheumatology and Clinical Immunology, Peking University First 
      Hospital, Beijing 100034, China.
FAU - Fan, Yong
AU  - Fan Y
FAU - Wang, Yu
AU  - Wang Y
FAU - Deng, Xuerong
AU  - Deng X
FAU - Ji, Lanlan
AU  - Ji L
FAU - Zhang, Xiaohui
AU  - Zhang X
FAU - Song, Zhibo
AU  - Song Z
FAU - Huang, Hong
AU  - Huang H
FAU - Gui, Yanni
AU  - Gui Y
FAU - Zhang, Haoze
AU  - Zhang H
FAU - Sun, Xiaoying
AU  - Sun X
FAU - Li, Guangtao
AU  - Li G
FAU - Zhao, Juan
AU  - Zhao J
FAU - Zhang, Zhuoli
AU  - Zhang Z
LA  - eng
PT  - Journal Article
DEP - 20231005
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (COVID-19 Vaccines)
SB  - IM
MH  - Humans
MH  - *Arthritis, Rheumatoid
MH  - Cohort Studies
MH  - *COVID-19/prevention & control
MH  - *COVID-19 Vaccines/adverse effects
MH  - East Asian People
MH  - Prospective Studies
MH  - *Vaccination/adverse effects
PMC - PMC10538871
COIS- None.
EDAT- 2023/03/16 06:00
MHDA- 2023/10/06 06:43
PMCR- 2023/10/05
CRDT- 2023/03/15 15:02
PHST- 2023/10/06 06:43 [medline]
PHST- 2023/03/16 06:00 [pubmed]
PHST- 2023/03/15 15:02 [entrez]
PHST- 2023/10/05 00:00 [pmc-release]
AID - 00029330-990000000-00441 [pii]
AID - CMJ-2022-1792 [pii]
AID - 10.1097/CM9.0000000000002562 [doi]
PST - epublish
SO  - Chin Med J (Engl). 2023 Oct 5;136(19):2324-2329. doi: 
      10.1097/CM9.0000000000002562.